No trading signal. Monitor for any future strategic shifts that may be influenced by Miller's Karuna/BMS experience, but this filing alone does not warrant action.
Price Chart
Executive Summary
Alto Neuroscience appointed Dr. Andrew Miller, founder of Karuna Therapeutics (acquired by Bristol Myers Squibb), to its Board of Directors, filling a vacancy created by expanding the board from six to seven members. Dr. Miller also joins the Nominating and Corporate Governance Committee. This is a routine board appointment with no material financial impact.
Key Facts
- Board expanded from six to seven directors effective March 16, 2026
- Andrew Miller, Ph.D., founder of Karuna Therapeutics (acquired by BMS), appointed as Class III director
- Miller will serve on the Nominating and Corporate Governance Committee, replacing Christopher Nixon Cox
- Miller determined independent under NYSE and SEC rules
- Standard non-employee director compensation: initial option for up to 48,200 shares (Black-Scholes value not exceeding $400,000), annual option grants, $40,000 annual cash retainer plus $5,000 for NCGC service
- No transactions between Miller and the company requiring disclosure under Item 404(a)
Financial Impact
Routine director compensation — initial option capped at $400,000 Black-Scholes value, annual cash retainers of $45,000 total. Immaterial relative to $717M market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001999480-26-000016 |
| Document: 0001999480-26-000016-index-headers.html | 0001999480-26-000016 |
| Document: 0001999480-26-000016-index.html | 0001999480-26-000016 |
| Document: 0001999480-26-000016.txt | 0001999480-26-000016 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | Institutional Cluster | $32.30 $34.25 | ▲ +6.04% | ▲ +8.00% | $23.19 (−28.20%) |
Jul 14, 2026 15w ago | 8-K | $27.80 $25.90 | ▲ +6.83% | ▲ +5.54% | $23.19 (+16.58%) |
Jul 14, 2026 15w ago | 424B5 | $27.80 $25.90 | ▲ +6.83% | ▲ +5.54% | $23.19 (+16.58%) |
Jul 13, 2026 15w ago | 8-K | $28.03 $27.54 | ▼ −1.75% | ▼ −0.96% | $23.19 (−17.27%) |
Jun 11, 2026 19w ago | Institutional Cluster | $21.47 $22.74 | ▲ +5.92% | ▲ +5.24% | $23.19 (+8.01%) |
May 29, 2026 21w ago | 3 | $19.80 $18.26 | ▼ −7.78% | ▼ −5.03% | $23.19 (+17.12%) |
May 28, 2026 21w ago | 8-K | $20.22 $18.85 | ▼ −6.78% | ▼ −6.73% | $23.19 (+14.69%) |
May 13, 2026 23w ago | 8-K | $22.85 $20.45 | ▼ −10.50% | ▼ −9.35% | $23.19 (+1.49%) |
Apr 21, 2026 27w ago | EFFECT | $25.59 $24.47 | ▼ −4.38% | ▼ −5.46% | $23.19 (−9.38%) |
Apr 10, 2026 28w ago | S-3 | $25.75 $27.33 | ▲ +6.14% | ▲ +2.84% | $23.19 (−9.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers